ACTU - Actuate Therapeutics, Inc. Common stock News

ACTU

Actuate Therapeutics, Inc. Common stock

1.51

2 x 1.50

1 x 1.53

bid

ask

0.07

5.21%

10:10 AM

timesize

Ytd	-75.25%
1y	-77.52%

1.41

day range

1.53

1.40

52 week range

9.22

Open	1.44	Prev Close	1.44	Low	1.41	High	1.53	Mkt Cap	36.25M
Vol	17.76K	Avg Vol	183.31K	EPS	-0.98	P/E	N/A	Forward P/E	N/A
Beta	N/A	Short Ratio	0.49	Inst. Own	53.05%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-13	50-d Avg	2.35	200-d Avg	4.60	1yr Est	0.00

ACTU News

benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com

Actuate Therapeutics' Elraglusib To Be Evaluated In BEACON2 Clinical Study To Identify, Proceed To T

Actuate Therapeutics, Inc. (NASDAQ:ACTU), a clinical-stage biopharmaceutical company focused on deve

globenewswire.com

Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Ne

- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and spons

benzinga.com

Actuate Therapeutics Features Post-Hoc Efficacy And Biomarker Analyses From Randomized Phase 2 Study

- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall surv

globenewswire.com

Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Bioma

- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall surv

benzinga.com

HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:AC

benzinga.com

Actuate Therapeutics Announces FDA Clearance Of IND For Phase 1/2 Study Of Oral Elraglusib In Advanc

Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical use

globenewswire.com

Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to

Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical use

invezz.com

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in

globenewswire.com

Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commer

benzinga.com

HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:AC

reuters.com

Actuate Therapeutics drug improves survival odds in pancreatic cancer trial

Twice as many advanced pancreas cancer patients who received an experimental drug developed by Actua

benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com

12 Health Care Stocks Moving In Friday's Pre-Market Session

benzinga.com

Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours?

Actuate Therapeutics shares surged 14.41% after-hours after Nature Medicine published Phase 2 data s

benzinga.com

12 Health Care Stocks Moving In Wednesday's After-Market Session

benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com

Actuate Announces Publication In Nature Medicine Reporting Phase 2 Data Showing Elraglusib + Chemoth

Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1

globenewswire.com

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doublin

CHICAGO and FORT WORTH, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ

benzinga.com

Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi

benzinga.com

HC Wainwright & Co. Maintains Buy on Actuate Therapeutics, Lowers Price Target to $15

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Actuate Therapeutics (NASDAQ:ACT

accessnewswire.com

Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformat

Meg Flippin, Benzinga Staff Writer CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / March 24, 2026

defenseworld.net

Gossamer Bio (NASDAQ:GOSS) versus Actuate Therapeutics (NASDAQ:ACTU) Critical Survey

Actuate Therapeutics (NASDAQ: ACTU - Get Free Report) and Gossamer Bio (NASDAQ: GOSS - Get Free Repo

benzinga.com

Actuate Therapeutics Launches Strategic Research Initiative To Combine Elraglusib With RAS Inhibitor

The combination strategy is designed to simultaneously block proliferative signaling through RAS inh

globenewswire.com

Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitor

CHICAGO and FORT WORTH, Texas, March 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ

globenewswire.com

Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:

benzinga.com

Actuate Therapeutics Intends To Initiate Phase 1/2 Clinical Program To Evaluate Oral Tablet Dosage F

Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-s

$Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers$

globenewswire.com

Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a

-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will in

benzinga.com

Actuate Therapeutics Says New Additional And Patient Survival, Biomarker Data From Treatment With El

Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall sur

globenewswire.com

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial De

CHICAGO and FORT WORTH, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:

defenseworld.net

Todd Thomson Sells 280,000 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock

Actuate Therapeutics, Inc. (NASDAQ: ACTU - Get Free Report) Director Todd Thomson sold 280,000 share

benzinga.com

Actuate Announces Results From Phase 1 Portion Of Phase 1/2 Clinical Study Evaluating Elraglusib As

Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewi

$Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers$

globenewswire.com

Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Re

CHICAGO and FORT WORTH, Texas, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:

zacks.com

Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?

Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing opt

benzinga.com

Actuate Therapeutics' Data From Its Phase 2 Trial Of Elraglusib In Metastatic Pancreatic Cancer Sele

Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-s

globenewswire.com

Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presenta

CHICAGO and FORT WORTH, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:

benzinga.com

Actuate Therapeutics Announces Publication Of New Data In Clinical Cancer Research From A Phase II S

Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.

zacks.com

How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06%

The average of price targets set by Wall Street analysts indicates a potential upside of 214.1% in A

benzinga.com

HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:AC

benzinga.com

HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:AC

benzinga.com

Actuate Therapeutics Q3 EPS $(0.25) Beats $(0.28) Estimate

Actuate Therapeutics (NASDAQ:ACTU) reported quarterly losses of $(0.25) per share which beat the ana

benzinga.com

HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:AC

benzinga.com

Actuate Therapeutics Advances Elraglusib As Potential Backbone Therapy For Pancreatic Cancer With Ph

Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials i

globenewswire.com

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory I

CHICAGO and FORT WORTH, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ

benzinga.com

12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com

Actuate Therapeutics Prices $15M Public Offering Of 2,142,858 Shares At A Price Of $7.00/Share

Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-st

globenewswire.com

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ

benzinga.com

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga.com

12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com

Actuate Therapeutics Announces Underwritten Public Offering Of Common Stock With 30-Day Option For A

Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-st